

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF CALIFORNIA

PAMELA COLEMAN, et al.,  
  
Plaintiffs,  
  
v.  
  
BOSTON SCIENTIFIC CORPORATION,  
et al.,  
  
Defendants.

1:10-cv-01968-OWW-SKO  
MEMORANDUM DECISION REGARDING  
MOTION TO DISMISS (Doc. 9)

**I. INTRODUCTION.**

Plaintiffs Pamela Coleman ("Coleman"), Mary Bower ("Bower"), and Kathleen Paison ("Paison") (collectively "Plaintiffs") proceed with an action for damages against Boston Scientific Corporation ("Defendant") and various Doe Defendants.

Defendant filed a motion to dismiss Plaintiffs' complaint on February 26, 2011. (Doc. 9). Plaintiffs filed opposition to the motion to dismiss on March 28, 2011. (Doc. 13). Defendant filed a reply on April 4, 2011. (Doc. 17).

**II. FACTUAL BACKGROUND.**

Plaintiffs are three individuals who underwent medical procedures described as "transvaginal tape, bladder sling, urethral suspension, and cystocele repair" in the United States between August 2005 and December 2006. Coleman, a resident of Bakersfield,

1 California, underwent her procedures in December 2006. Bower, a  
2 resident of Grand Rapids, Michigan, underwent her procedure in  
3 April 2006. Paison, a resident of Westland, Michigan, underwent  
4 her procedure in August 2005. The complaint does not allege where  
5 each Plaintiff had her procedure performed.

6 Defendant designed, researched, developed, manufactured,  
7 tested, marketed, advertised, promoted, distributed, and sold  
8 synthetic surgical mesh devices purported to correct and restore  
9 normal vaginal structure secondary to pelvic organ prolapse.

10 Plaintiffs' received implants of mesh devices manufactured,  
11 marketed, and sold by Defendant in connection with their respective  
12 transvaginal tape, bladder sling, urethral suspension, and  
13 cystocele repair procedures. Since implantation of the mesh  
14 devices, Plaintiffs have suffered from erosion, shrinkage, and  
15 extrusion of mesh from one or more of the mesh devices, causing  
16 urinary retention, severe persistent pain, including dyspareunia,  
17 and numerous surgical procedures to remove the mesh devices.

18 At all times relevant, the mesh devices were widely advertised  
19 and promoted by Defendants as a safe and effective treatment for  
20 pelvic organ prolapse, rectocele, enterocele, and stress urinary  
21 incontinence. Defendants minimized the risks posed to patients by  
22 implantation of the mesh devices. At all times relevant,  
23 Defendants knew that the devices were not safe because the mesh  
24 eroded and otherwise malfunctioned causing injuries from erosion,  
25 extrusion, infection, sepsis, chronic foreign body invasion, dense  
26 adhesions, and worsening dyspareunia. Defendants made false  
27 representations regarding the consistency, safety, reliability, and  
28 performance of the mesh devices in published literature and adverse

1 event reports. Defendants failed to disclose to physicians,  
2 patients, or Plaintiffs that their mesh devices were subject to  
3 erosion or scar tissue formation causing injuries.

4 Defendants continued to promote the mesh devices as safe and  
5 effective even when no clinical trials had been done; in doing so,  
6 Defendants concealed the known risks and failed to warn of known or  
7 scientifically knowable dangers and risks associated with the mesh  
8 devices for pelvic organ prolapse, rectocele, enterocele, and  
9 stress urinary incontinence.

### 10 **III. LEGAL STANDARD.**

11 Dismissal under Rule 12(b)(6) is appropriate where the  
12 complaint lacks sufficient facts to support a cognizable legal  
13 theory. *Balistreri v. Pacifica Police Dep't*, 901 F.2d 696, 699 (9th  
14 Cir.1990). To sufficiently state a claim to relief and survive a  
15 12(b)(6) motion, the pleading "does not need detailed factual  
16 allegations" but the "[f]actual allegations must be enough to raise  
17 a right to relief above the speculative level." *Bell Atl. Corp. v.*  
18 *Twombly*, 550 U.S. 544, 555, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007).  
19 Mere "labels and conclusions" or a "formulaic recitation of the  
20 elements of a cause of action will not do." *Id.* Rather, there must  
21 be "enough facts to state a claim to relief that is plausible on  
22 its face." *Id.* at 570. In other words, the "complaint must contain  
23 sufficient factual matter, accepted as true, to state a claim to  
24 relief that is plausible on its face." *Ashcroft v. Iqbal*, --- U.S.  
25 ----, ----, 129 S.Ct. 1937, 1949, 173 L.Ed.2d 868 (2009) (internal  
26 quotation marks omitted).

27 The Ninth Circuit has summarized the governing standard, in  
28 light of *Twombly* and *Iqbal*, as follows: "In sum, for a complaint to

1 survive a motion to dismiss, the nonconclusory factual content, and  
2 reasonable inferences from that content, must be plausibly  
3 suggestive of a claim entitling the plaintiff to relief." Moss v.  
4 U.S. Secret Serv., 572 F.3d 962, 969 (9th Cir.2009) (internal  
5 quotation marks omitted). Apart from factual insufficiency, a  
6 complaint is also subject to dismissal under Rule 12(b)(6) where it  
7 lacks a cognizable legal theory, Balistreri, 901 F.2d at 699, or  
8 where the allegations on their face "show that relief is barred"  
9 for some legal reason, Jones v. Bock, 549 U.S. 199, 215, 127 S.Ct.  
10 910, 166 L.Ed.2d 798 (2007).

11 In deciding whether to grant a motion to dismiss, the court  
12 must accept as true all "well-pleaded factual allegations" in the  
13 pleading under attack. Iqbal, 129 S.Ct. at 1950. A court is not,  
14 however, "required to accept as true allegations that are merely  
15 conclusory, unwarranted deductions of fact, or unreasonable  
16 inferences." Sprewell v. Golden State Warriors, 266 F.3d 979, 988  
17 (9th Cir.2001). "When ruling on a Rule 12(b)(6) motion to dismiss,  
18 if a district court considers evidence outside the pleadings, it  
19 must normally convert the 12(b)(6) motion into a Rule 56 motion for  
20 summary judgment, and it must give the nonmoving party an  
21 opportunity to respond." United States v. Ritchie, 342 F.3d 903,  
22 907 (9th Cir.2003). "A court may, however, consider certain  
23 materials-documents attached to the complaint, documents  
24 incorporated by reference in the complaint, or matters of judicial  
25 notice-without converting the motion to dismiss into a motion for  
26 summary judgment." Id. at 908.

27 ///

28 ///

1 **IV. DISCUSSION.**

2 **A. Product Identification**

3 As an initial matter, Defendants contend that the complaint  
4 does not allege facts sufficient to permit identification of the  
5 particular "mesh products" underlying Plaintiffs' claims.  
6 Defendants argue that, absent identification of a specific product,  
7 the complaint fails to plead the specific facts required to raise  
8 a plausible claim for relief. (Doc. 9, MTD at 3-4). Defendants  
9 cite *Timmons v. Linvatec Corp.*, 263 F.R.D. 582, 584-85 (C.D. Cal.  
10 2010) and *Adams v. I-Flow Corp.*, *Adams v. I-Flow Corp.*, 2010 WL  
11 1339948 \*3 (C.D. Cal. 2010); 2010 U.S. Dist. LEXIS 33066, for the  
12 proposition that "if a plaintiff fails to specifically identify the  
13 product at issue in their Complaint, they [sic] cannot satisfy the  
14 necessary pleading requirements and their claims must be  
15 dismissed." (MTD at 4). Neither *Timmons* nor *Adams* support the  
16 onerous pleading burden Defendants advance.

17 In *Adams*, the complaint did not allege that any of the named  
18 defendants manufactured the allegedly defective device that caused  
19 the plaintiffs injuries:

20 The Complaint does not allege that any particular  
21 plaintiff was administered a particular drug through a  
22 particular pain pump that was manufactured by a  
23 particular defendant. Instead, plaintiffs plead only  
24 generally that they were injured by pain pumps and  
25 anesthetics of the type made by defendants. By suing  
26 fourteen (14) "Defendant Pain Pump Manufacturers" and  
27 eight (8) "Defendant Anesthetic Manufacturers," the  
28 Complaint at most alleges that the individual defendants  
theoretically could have been the one who manufactured  
the pain pump or anesthetic used following each  
plaintiff's surgery. But, the Complaint never specifies  
that any one of the defendants, as opposed to the 21  
other defendants, caused each plaintiff's claimed injury.  
As such, plaintiffs plead nothing more than the sheer  
possibility that any particular defendant might have  
manufactured the product that allegedly injured each

1 plaintiff. This sort of speculative pleading is not  
2 permitted under the plain text of Rule 8, which requires  
3 a "statement of the claim showing that the pleader is  
4 entitled to relief."

5 *Id.* at 7-8. Similarly, the complaint in *Timmons*:

6 allege[d] Mrs. Timmons sustained a shoulder injury as a  
7 result of receiving an unidentified "anesthetic  
8 medication." Plaintiffs sue[d] AstraZeneca as one of  
9 eight "defendant anesthetic manufacturers," but fail[ed]  
10 to allege that AstraZeneca manufactured the particular  
11 medication administered to Ms. Timmons after her single  
12 surgery. Thus, the Complaint [did] not allege that  
13 AstraZeneca, as opposed to one of the other anesthetic  
14 manufacturer defendants, caused Plaintiffs' alleged  
15 injuries.

16 263 F.R.D. at 584. *Timmons* does not support Defendants' ambitious  
17 construction of Rule 8, which would require plaintiffs in any  
18 medical product liability case to "specifically identify" the  
19 products at issue in order to satisfy federal pleading standards.  
20 Rather, *Timmons* stands for the unremarkable proposition that a  
21 plaintiff must allege that a particular defendant caused her  
22 injury. See *id.* ("The Complaint fails to state a claim against  
23 AstraZeneca under Rule 8, *Twombly*, and *Iqbal*. To state a claim  
24 against AstraZeneca, Plaintiffs must allege that AstraZeneca  
25 caused their injuries.").

26 Imposing on plaintiffs the burden of specifically identifying  
27 a device by reference to a specific product line or model number,  
28 without the benefit of discovery, could create an insurmountable  
pleading burden in some cases. For example, where medical records  
only reflect general information about the type of device used in  
a given procedure, a plaintiff may be unable to plead with  
specificity the exact product at issue in the pleading phase of her  
case. See *Butts v. Tyco Healthcare Group LP*, 2007 U.S. Dist. LEXIS  
37847 \*4 (N.D. Ga. 2007) (noting difficulty plaintiff faced in

1 tailoring appropriate discovery where doctor's post-operative  
2 report did not identify the specific model of the medical device  
3 employed during plaintiff's procedure). Where information  
4 regarding the specific medical device at issue is unavailable  
5 during the pleading stage, a plaintiff may have to rely on  
6 circumstantial evidence, such as contracts between a medical  
7 facility and a device manufacturer, to establish that the device  
8 that harmed her was manufactured by a particular defendant; the  
9 district court's analysis of a discovery dispute in *Butts* is  
10 instructive on this point:

11 defendants have objected to the plaintiff's discovery  
12 requests on the grounds that the plaintiff has failed to  
13 establish who manufactured the allegedly defective  
14 stapler and, even assuming that it was indeed the  
15 defendants who manufactured it, the plaintiff does not  
16 identify which of the defendants' products was used  
17 during her surgery. Specifically, the defendants assert  
18 that because the reference to a single "# 25 EEA stapler"  
19 in the post-operative report does not identify any  
20 specific stapler, but could describe several different  
21 staplers manufactured by the defendants, responding to  
22 the plaintiff's interrogatories and requests for  
23 production is unduly burdensome and would produce  
24 information on unrelated products.

25 ...[P]laintiff asserts that she is not required to  
26 specifically identify the allegedly defective product at  
27 this juncture and that information on any stapler  
28 manufactured by the defendants with similar functions,  
operations, designation, or nomenclature as the "# 25 EEA  
stapler" is discoverable.

The sole factual basis for the action against the  
defendants...is the post-operative report by the  
physician who performed the plaintiff's gastric bypass  
surgery. That report notes the use and apparent  
malfunction of a "# 25 EEA stapler," which "was married  
to the anvil and stapler was closed and fired."

...However, the doctor's post-operative report does not  
identify the specific model of EEA [] stapler used or its  
manufacturer. Instead, the report simply refers to a "#  
25 EEA stapler." Accordingly, because the plaintiff's  
complaint uses that report as the basis for her claims  
against Tyco and United States Surgical, the defendants

1 assert that two questions must be answered before  
2 discovery can proceed: (1) whether the defendants  
3 manufactured the stapler used in the plaintiff's surgery,  
4 and (2) if so, which of the defendants' staplers is the  
5 one referred to as the "# 25 EEA stapler."

6 ...[Plaintiff] has made no direct showing that Tyco  
7 Healthcare or United States Surgical manufactured the  
8 stapler used during her surgery. Rather, the plaintiff  
9 points to a contract between the defendants and Emory  
10 Hospitals that establishes United States Surgical as the  
11 exclusive provider of gastric bypass staplers.  
12 Ostensibly, this contract shows that although it is  
13 unknown whether the defendants actually manufactured the  
14 stapler used in the plaintiff's surgery, it at least  
15 establishes a good faith basis to proceed with discovery  
16 against the defendants. Without any direct evidence, this  
17 court concludes that while the plaintiff is on shaky  
18 ground in this regard, the existence of an exclusive  
19 contract with the defendants is persuasive circumstantial  
20 evidence sufficient to proceed with discovery against the  
21 defendants as the manufacturers of the allegedly  
22 defective stapler.

23 *Id.* at 2-5 (citations to the record omitted).

24 Like the defendants in *Butts*, Defendant contends that  
25 Plaintiffs' failure to identify the specific device subject to  
26 their complaint is insufficient. In its reply, Defendant complains  
27 that it manufactures "at least nine separate products that involve  
28 mesh that could potentially fall within Plaintiffs' vague  
29 definition." (Doc. 17, Reply at 2). Defendants state that the mesh  
30 products it manufactures

31 include, but are not limited to, Advantage Fit System,  
32 Advantage Transvaginal Mid-Urethral Sling System, Lynx  
33 Suprapubic Mid-Urethral Sling System, Obtryx  
34 Tansobturator Mid-Urethral Sling System, Prefyx PPS  
35 System, Solyx Sis System, Pinnacle Posterior Pelvic Floor  
36 Repair Kit, Uhold Vaginal Support System, and Polyform  
37 Synthetic Mesh. The nine above-referenced mesh products  
38 are distinguishable, with each having its own separate  
39 design, indications, directions for use, techniques for  
40 implantation, and warnings.

41 (Id.).



1           Rather than suggest more specific pleading is required,  
2 Defendant's discussion of its extensive mesh products line reveals  
3 the injustice that would result from requiring specific  
4 identification of a precise product during the pleading phase of a  
5 case, without discovery. It is axiomatic that medical patients  
6 such as Plaintiffs are not always in a position to know whether an  
7 Obtryx Tansobturator Mid-Urethral Sling System or an Advantage  
8 Transvaginal Mid-Urethral Sling System was placed inside of them  
9 while they were anaesthetized. Rather, manufacturers are in a  
10 better position to ascertain which of their devices was likely used  
11 in a given procedure, because they can compare each of their  
12 products' unique "design[s], indications, directions for use, [and]  
13 techniques for implantation" to the allegations of the complaint  
14 concerning when, where, and for what medical purpose a plaintiff's  
15 surgical procedure was performed.

16           As the Seventh Circuit Court of Appeal recognized recently,  
17 there are no special pleading requirements for product liability  
18 claims or medical device claims in particular. *Bausch v. Stryker*  
19 *Corp.*, 630 F.3d 546, 558 (7th Cir. 2010). The federal standard of  
20 notice pleading applies to defective medical device claims: so long  
21 as the complaint alleges facts sufficient to meet the  
22 "plausibility" standard applied in *Iqbal* and *Twombly*, dismissal  
23 under Rule 12 is inappropriate. *Id.* Pleading defective medical  
24 device claims is difficult, and discovery is often necessary before  
25 a plaintiff can fairly be expected to provide specific details.  
26 *See id.*

27           Plaintiffs' complaint provides information regarding the types  
28 of surgical procedures they underwent, as well as a detailed

1 technical description of the devices they allege injured them:  
2 "mesh devices purported to correct and restore normal vaginal  
3 structure secondary to pelvic organ prolapse." The complaint also  
4 states that Defendants "sought and obtained [FDA] approval to  
5 market mesh [sic] products and/or its monofilament polypropylene  
6 mesh component under section 510(k) of the Medical Device  
7 Amendment." These allegations provide further description of the  
8 type of product. Nevertheless, the complaint contains ambiguities.

9 First, the complaint does not clearly allege where each  
10 Plaintiff underwent their respective procedures. When a Plaintiff  
11 is unable to identify a specific medical device in her complaint,  
12 information revealing when, where, and why a procedure was  
13 performed should be pleaded to assist manufacturers in identifying  
14 which of its products is implicated. As Plaintiffs do not allege  
15 which state they underwent their procedures in, let alone the  
16 names of the medical facilities involved, the complaint does not  
17 comply with Rule 8.

18 Second, the complaint is ambiguous with respect to whether  
19 each Plaintiff had the same type of mesh device implanted. The  
20 complaint suggests that Plaintiffs seek to assert claims based on  
21 the failure of more than one mesh device manufactured by Defendant.  
22 Paragraph 11 of the complaint states that the term "mesh devices"  
23 refers to Defendant's products "collectively." (Compl. at 3).  
24 Critically, paragraph 14 alleges that Plaintiffs were injured by  
25 "extrusion of mesh from *one or more* of the Mesh Devices." (Id. at  
26 3) (emphasis added). Plaintiffs complaint must be amended to (1)  
27 state clearly whether Plaintiffs' claims are based on one defective  
28 device common to all Plaintiffs, or whether claims are asserted

1 based on multiple mesh devices that share a common defect; and (2)  
2 state clearly the location where each Plaintiffs' respective  
3 procedure was performed.

#### 4 **B. Implied Warranty Claim**

5 Defendants correctly assert that Plaintiffs' claims for breach  
6 of implied warranty are not cognizable. Under California law,  
7 privity between parties is required for either claim of implied  
8 warranty. *E.g., Evraets v. Intermedics Intraocular, Inc.*, 29 Cal.  
9 App. 4th 779, 857 (Cal. Ct. App. 1994) (noting that California  
10 Commercial Code section 2315 requires that a buyer rely on sellers'  
11 skill or judgment in order to have a cognizable implied warranty  
12 claim and rejecting implied warranty claim against medical device  
13 manufacturer); *Blanco v. Baxter Healthcare Corp.*, 158 Cal. App. 4th  
14 1039, 1058 (2008) (rejecting implied warranty claim against medical  
15 device manufacture because of lack of privity with citation to  
16 *Evraets*); *accord Clemens v. Daimler Chrysler Corp.*, 534 F.3d 1017,  
17 1023 (9th Cir.2008) (plaintiff asserting breach of implied warranty  
18 claims must stand in vertical contractual privity with the  
19 defendant). Plaintiffs do not contend otherwise. Plaintiffs'  
20 implied warranty claim is DISMISSED WITH PREJUDICE.

#### 21 **C. Express Warranty Claims**

22 Defendants contention that privity is an element of an express  
23 warranty claim is incorrect. *E.g., Evraets*, 29 Cal. App. 4th at  
24 857 n.4 ("privity is not a requirement for actions based upon an  
25 express warranty"); *Fieldstone Co. v. Briggs Plumbing Products,*  
26 *Inc.*, 54 Cal. App. 4th 357, n.10 (Cal. Ct. App. 1997) ("As a  
27 general rule, privity of contract is a required element of an  
28 express breach of warranty cause of action. However, there is an

1 exception where plaintiff's decision to purchase the product was  
2 made in reliance on the manufacturers' written representations in  
3 labels or advertising materials.") (citations omitted). However,  
4 Plaintiffs express warranty claims must be dismissed, as the  
5 complaint does not allege facts sufficient to give rise to a  
6 plausible basis to believe that Plaintiffs relied on any  
7 representations made by Defendants. See, e.g., *id.* Plaintiffs'  
8 conclusory allegations that Defendants advertised their products as  
9 safe and effective lack even general information describing such  
10 alleged conduct. As one district court has aptly noted, conclusory  
11 allegations such as those advanced by Plaintiffs are insufficient  
12 to support a plausible basis for an express warranty claim:

13       Evraets stands as clear authority that at least at the  
14 pleading stage, California law permits a claim for breach  
15 of an express warranty to go forward under circumstances  
16 [where reliance is alleged]. That said, the complaint as  
17 presently constituted fails to allege any express  
warranties actually made by Stryker, except in the most  
general and conclusory terms. Accordingly, the claim for  
breach of express warranty will be denied, with leave to  
amend.

18 *Quatela v. Stryker Corp.*, 2010 U.S. Dist. LEXIS 133706 \* 4-6 (N.D.  
19 Cal. 2010). Plaintiffs' express warranty claims are DISMISSED,  
20 with leave to amend.

#### 21 **D. Fraud Based Claims**

22       Federal Rule of Civil Procedure 9(b) imposes an elevated  
23 pleading standard with respect to claims that "sound in fraud" or  
24 are "grounded in fraud." *Kearns v. Ford Motor Co.*, 567 F.3d 1120,  
25 1125 (9th Cir. 2009). "To comply with Rule 9(b), allegations of  
26 fraud must be specific enough to give defendants notice of the  
27 particular misconduct which is alleged to constitute the fraud."  
28 *Swartz v. KPMG LLP*, 476 F.3d 756, 764 (9th Cir. 2007) (internal

1 quotation marks omitted). Allegations of fraud must include the  
2 "time, place, and specific content of the false representations as  
3 well as the identities of the parties to the misrepresentations."  
4 *Id.* (internal quotation marks omitted). The "[a]llegations of fraud  
5 must be accompanied by the who, what, when, where, and how of the  
6 misconduct charged." *Kearns v. Ford Motor Co.*, 567 F.3d 1120, 1124  
7 (9th Cir. 2009) (internal quotation marks omitted). A plaintiff  
8 alleging fraud "must set forth more than the neutral facts  
9 necessary to identify the transaction. The plaintiff must set forth  
10 what is false or misleading about a statement, and why it is  
11 false." *Vess v. Ciba-Geigy Corp. USA*, 317 F.3d 1097, 1106 (9th Cir.  
12 2003).

13 Plaintiffs' general allegations do not comply with Rule 9(b)'s  
14 particularity requirements. Plaintiffs' attempt to rely on cases  
15 such as *Glen Holly Ent., Inc., v. Tektronix, Inc.*, 100 F. Supp. 2d  
16 1086, 1095 (C.D. Cal. 1999) for the proposition that "Rule 9(b) may  
17 be relaxed as to matters peculiarly within the opposing party's  
18 knowledge" is unavailing; the complaint does not allege facts  
19 sufficient to support an inference that Defendants knew of the  
20 alleged defects of their products at any time relevant to the  
21 complaint or that any false representations were made to Plaintiffs  
22 on which they relied. Plaintiffs' fraud based claims are  
23 DISMISSED, with leave to amend.

#### 24 **E. Negligent Misrepresentation Claims**

25 Plaintiffs' negligent misrepresentation claim is based on  
26 Plaintiffs' conclusory contention that "adverse event reports  
27 specifically related to the Mesh Devices showed the Mesh Devices to  
28 be defective and dangerous when used in the intended manner."

1 (Compl. at 11). The complaint does not allege facts sufficient to  
2 give rise to an inference that, at the time Defendants made alleged  
3 representations concerning the safety of their mesh devices,  
4 Defendants had reason to know of the dangers Plaintiffs complain of  
5 or that they made any misrepresentations without a reasonable basis  
6 for believing them to be true. *Inter alia*, the complaint does not  
7 allege when such representations were made. Plaintiffs' negligent  
8 misrepresentation claims are DISMISSED, with leave to amend.

9 **F. UCL Claims**

10 As discussed above, Plaintiffs' complaint is insufficient with  
11 respect fraud and misrepresentation based claims. The complaint is  
12 fatally vague with respect to which mesh devices are the subject of  
13 this action. As there are no predicate claims alleged in the  
14 complaint, Plaintiffs' UCL claims are DISMISSED, without prejudice.

15 **G. Venue and Joinder**

16 Defendant contends that venue for the claims of Plaintiffs who  
17 reside in Michigan is improper in the eastern district, and that  
18 such Plaintiffs' claims are improperly joined in this action. The  
19 propriety of joinder and venue cannot be ascertained due to the  
20 pleading deficiencies discussed above. Defendant may renew its  
21 objections to joinder and venue after Plaintiffs provide an amended  
22 complaint.

23 **ORDER**

24 For the reasons stated, IT IS ORDERED:

- 25 1) Plaintiffs' implied warranty claims are DISMISSED, with  
26 prejudice;
- 27 2) Plaintiff's remaining claims are DISMISSED, without  
28 prejudice;

1 3) Plaintiff's shall file an amended complaint within sixty  
2 days of receiving electronic notice of this decision.  
3 Defendant shall file responsive pleading within twenty days of  
4 service of an amended complaint; and

5 4) Defendant shall submit a form of order consistent with this  
6 memorandum decision within five days of receiving electronic  
7 notice of this decision.

8  
9 IT IS SO ORDERED.

10 Dated: April 20, 2011

/s/ Oliver W. Wanger  
UNITED STATES DISTRICT JUDGE